- Home
- PNI vs SKYE Comparison
PNI vs SKYE Comparison
Compare PNI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- SKYE
- Stock Information
- Founded
- PNI 2002
- SKYE 2012
- Country
- PNI United States
- SKYE United States
- Employees
- PNI N/A
- SKYE N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PNI Finance
- SKYE Health Care
- Exchange
- PNI Nasdaq
- SKYE Nasdaq
- Market Cap
- PNI 82.7M
- SKYE 80.7M
- IPO Year
- PNI N/A
- SKYE N/A
- Fundamental
- Price
- PNI $6.69
- SKYE $1.44
- Analyst Decision
- PNI
- SKYE Buy
- Analyst Count
- PNI 0
- SKYE 6
- Target Price
- PNI N/A
- SKYE $16.60
- AVG Volume (30 Days)
- PNI 26.4K
- SKYE 1.7M
- Earning Date
- PNI 01-01-0001
- SKYE 05-09-2025
- Dividend Yield
- PNI 4.76%
- SKYE N/A
- EPS Growth
- PNI N/A
- SKYE N/A
- EPS
- PNI N/A
- SKYE N/A
- Revenue
- PNI N/A
- SKYE N/A
- Revenue This Year
- PNI N/A
- SKYE N/A
- Revenue Next Year
- PNI N/A
- SKYE N/A
- P/E Ratio
- PNI N/A
- SKYE N/A
- Revenue Growth
- PNI N/A
- SKYE N/A
- 52 Week Low
- PNI $6.03
- SKYE $1.14
- 52 Week High
- PNI $7.89
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- PNI 29.75
- SKYE 40.43
- Support Level
- PNI $6.64
- SKYE $1.26
- Resistance Level
- PNI $6.91
- SKYE $3.73
- Average True Range (ATR)
- PNI 0.15
- SKYE 0.34
- MACD
- PNI -0.03
- SKYE 0.04
- Stochastic Oscillator
- PNI 25.00
- SKYE 11.40
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.